In particular, MYCN and the ARF/MDM2/p53 axis are connected in an elaborate gene regulatory network [17], a plausible explanation for why neuroblastoma’s clinical outcome is non-linearly related to MYCN expression [18]. The gene discussed is MDM2; the disease is neuroblastoma.